Company intelligence / Profile preview

Meridian Lab

Buffalo Grove, Illinois, United Statesmeridian-lab.com ↗

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Meridian Lab achieved FDA approval (2022) for ML141, a proprietary docetaxel injectable with improved safety by eliminating Polysorbate 80; is advancing a Polysorbate 80-free cabazitaxel formulation; and is developing a PARP+ATR dual inhibitor targeting prostate cancer[1][2][3].

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

ML141

Commercial

Indications: cancer

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Meridian Lab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meridian Lab.

Explore the full profile